Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
16,155,340
-
Shares change
-
+1,050,882
-
Total reported value, excl. options
-
$944,400,680
-
Value change
-
+$68,408,989
-
Number of buys
-
48
-
Number of sells
-
-39
-
Price
-
$58.51
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2021
114 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2021.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,155,340 shares
of 30,284,111 outstanding shares and own 53.35% of the company stock.
Largest 10 shareholders include FMR LLC (3,504,798 shares), ORBIMED ADVISORS LLC (1,679,417 shares), Deep Track Capital, LP (1,300,000 shares), BlackRock Inc. (1,286,526 shares), ALKEON CAPITAL MANAGEMENT LLC (926,433 shares), Nantahala Capital Management, LLC (796,698 shares), VANGUARD GROUP INC (733,720 shares), STATE STREET CORP (654,992 shares), First Light Asset Management, LLC (552,098 shares), and FRANKLIN RESOURCES INC (394,678 shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.